Yinjia Bio Honored Again as One of CHC-CITIC Securities' 'Top 50 Most Valuable Medical & Health Enterprises of 2024'

On May 15, 2025, the "2024 China Healthcare Industry Investment and Financing Honor Roll" was officially announced.YINJIA BIOSCIENCES Honored on "Top 50 Most Investment-Worthy Healthcare Companies in 2024" List for Its Innovative Technology R&D Strength, Forward-Looking Strategic Layout, and Industry Leadership Practices.This is the company's second time winning this award following its first win in 2022, showcasing YINJIA BIOSCIENCES' comprehensive competitiveness and sustainable development potential in the biomedicine and healthcare field.

As a witness and driving force in the development of China's healthcare industry, the annual list of the most investment-worthy companies in healthcare has become an important benchmark for measuring a company’s overall strength. YINJIA BIOSCIENCES is deeply grateful for the long-term trust and support from CITIC Securities CHC. This honor not only affirms our past technological accumulation but also serves as both the driving force and motivation for the company to maintain rapid growth in the future.

In the past few years, the biopharmaceutical industry has undergone the dual tests of pandemic impact and deep industrial adjustment. Facing the economic adjustments and changes in China and internationally in the post-pandemic era, as well as challenges such as market uncertainty and pressure to reduce investment, YINJIA BIOSCIENCES has risen against the odds. Adhering to the belief that "innovation builds core competitiveness," the company has continued to intensify its efforts in technological breakthroughs and product iteration. Collaborating with upstream and downstream partners, YINJIA BIOSCIENCES has advanced joint technological research, coordinated production capacity, and built an integrated R&D, production, and sales resilient ecosystem, accelerating the company's development pace.

Dr. Wu Yifei, founder of YINJIA BIOSCIENCES, stated"Receiving this honor twice within three years, we cherish it deeply. This recognition carries more of the expectations and encouragement from our industry peers towards YINJIA BIOSCIENCES. Moving forward, we will remain true to our original mission, continue to solidify our foundation through 'technological expertise,' expand our boundaries via 'ecosystem co-construction,' and adhere to the 'symbiotic win-win' ecological philosophy, providing a reliable and trustworthy choice for global life science research and innovative healthcare development."

YINJIA BIOSCIENCES is a technology-based platform company dedicated to the widespread application of proteins in biopharmaceuticals and other key areas related to people's livelihood. As a high-end protein raw material (antigen, antibody, and enzyme) and quality control testing kit manufacturer, it has completed three rounds of financing led by top investment institutions such as CDH Investments, Gaorong Capital, and CMB International within just over four years since its establishment. To date, the company has built a relatively complete intelligent design and complex process development platform for high-end proteins (antigens, antibodies, enzymes, and specialty proteins), as well as a therapeutic biologics quality control evaluation system testing reagent development platform. So far, it has successfully developed more than 200 core raw materials that are applied in cutting-edge fields such as new drug research and development, cell therapy, vaccines, organoids, and molecular/immunodiagnostic. Recently, it launched core raw materials and scarce quality control safety evaluation testing kits that empower ADC new drug research and production. Meanwhile, YINJIA BIOSCIENCES continues to strengthen its capabilities based on microbial genetic engineering and protein engineering, building out a comprehensive synthetic biology technology platform to inject new options and vitality into the development of various innovative and scarce proteins. As the platform improves and evolves, YINJIA BIOSCIENCES' technologies and products will become more adaptable across industries, providing stable and reliable products and services to a wider range of sectors.